Asset Acquisition Consideration Transferred, Liabilities

No definition available.

Name:	avtx_AssetAcquisitionConsiderationTransferredLiabilities
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Collaborative Agreement, Milestone Payment

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeAgreementMilestonePayment
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Collaborative Arrangement, License Rights Royalty Percentage

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementLicenseRightsRoyaltyPercentage
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Cumulative Milestone Payment Expense Recognized to Date

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsCumulativeMilestonePaymentExpenseRecognizedToDate
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement Rights And Obligations License Fee

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsLicenseFee
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Maximum Aggregate Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsMaximumAggregateMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights and Obligations, Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Rights And Obligations, Upfront Fee

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRightsAndObligationsUpfrontFee
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Collaborative Arrangement, Royalty Term

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementRoyaltyTerm
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Collaborative Arrangement, Termination Notice

+ References

No definition available.

+ Details

Name:	avtx_CollaborativeArrangementTerminationNotice
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingent Milestone Payment

+ References

No definition available.

+ Details

Name:	avtx_ContingentMilestonePayment
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Contingent Milestone Upfront Payment Percentage

+ References

No definition available.

+ Details

Name:	avtx_ContingentMilestoneUpfrontPaymentPercentage
Namespace Prefix:	avtx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, License Agreement Expiration Term

+ References

No definition available.

+ Details

Name:	avtx_ContractWithCustomerLicenseAgreementExpirationTerm
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Contract With Customer, Revenue Recognized to Date From Milestone Payments

+ References

No definition available.

+ Details

Name:	avtx_ContractWithCustomerRevenueRecognizedToDateFromMilestonePayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Maximum Potential Payments

+ References

No definition available.

+ Details

Name:	avtx_MaximumPotentialPayments
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Cash Payment Percentage

+ References

No definition available.

+ Details

Name:	avtx_MilestoneCashPaymentPercentage
Namespace Prefix:	avtx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone Equity Payment Percentage

+ References

No definition available.

+ Details

Name:	avtx_MilestoneEquityPaymentPercentage
Namespace Prefix:	avtx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration Amount

+ References

No definition available.

+ Details

Name:	avtx_RevenueRemainingPerformanceObligationVariableConsiderationAmount
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Royalty Agreement, Buyout Option, Percentage of Net Present Value of Royalty Payments

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementBuyoutOptionPercentageOfNetPresentValueOfRoyaltyPayments
Namespace Prefix:	avtx_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Agreement, Payment Received

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPaymentReceived
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty Agreement, Period After Public Launch to Terminate Agreement

+ References

No definition available.

+ Details

Name:	avtx_RoyaltyAgreementPeriodAfterPublicLaunchToTerminateAgreement
Namespace Prefix:	avtx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Payment Paid

+ References

No definition available.

+ Details

Name:	avtx_UpfrontPaymentPaid
Namespace Prefix:	avtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of liability recognized from contingent consideration in asset acquisition.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for the settlement of litigation or for other legal issues during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForLegalSettlements
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Value of stock issued as a result of the exercise of stock options.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

+ Details

Name:	us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=avtx_AlmataBioTransactionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX301OutLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	avtx_MilestoneAxis=avtx_MilestoneThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_LillyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX009LillyLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_KyowaKirinCoLtdKKCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX002KKCLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_CHOPLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AstellasPharmaIncAstellasMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX006Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_AVTX006AstellasLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AltoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_ESMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX406LicenseAssignmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=avtx_AUGTherapeuticsLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=avtx_PurchaseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=avtx_AVTX800SeriesAssetSaleMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details)							1 Months Ended			3 Months Ended			9 Months Ended
Commitments and Contingencies (Details)	Mar. 27, 2024 USD ($)	Oct. 27, 2023 USD ($)	May 28, 2021 USD ($)	Mar. 25, 2021 USD ($)	Feb. 03, 2020 USD ($)	Jul. 15, 2019 USD ($)	Oct. 31, 2024 USD ($)	Apr. 30, 2024 USD ($)	Jul. 31, 2019 USD ($)	Sep. 30, 2026 USD ($)	Jun. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Sep. 30, 2026 USD ($)	Sep. 30, 2025 USD ($)	Mar. 31, 2024 USD ($)	Mar. 28, 2024 USD ($)	Jun. 09, 2021 USD ($)
Other Commitments [Line Items]
Issuance of common stock from exercise of stock options										$ 2,540,000			$ 9,950,000
Issuance of common stock in cash												$ 14,370,000	404,912,000	$ 14,370,000
Royalty agreement, payment received									$ 2,000,000.0
Period after public launch to terminate agreement									3 years
Net present value of royalty payments (as a percent)									75.00%
AlmataBio Transaction
Other Commitments [Line Items]
Cash payments to acquire assets								$ 7,500,000
Contingent consideration															$ 5,000,000.0
Contingent consideration										0
AVTX-301 Out-License
Other Commitments [Line Items]
Licensed product expiration term			10 years
Milestone One \| AlmataBio Transaction
Other Commitments [Line Items]
Contingent consideration																$ 5,000,000.0
Milestone Two \| AlmataBio Transaction
Other Commitments [Line Items]
Contingent consideration											$ 15,000,000.0					$ 15,000,000.0
Milestone Three
Other Commitments [Line Items]
Collaborative agreement, milestone payment							$ 5,000,000.0
Milestone Three \| AlmataBio Transaction
Other Commitments [Line Items]
License agreement term											90 days
Upfront payment paid											$ 2,250,000
Contingent consideration											15,000,000.0				$ 15,000,000.0
Collaborative agreement, milestone payment											2,600,000
Issuance of common stock from exercise of stock options											2,250,000
Issuance of common stock in cash											$ 5,125,000
Milestone cash payment (as a percent)											0.50
Milestone equity payment (as a percent)											0.50
Contingent consideration											$ 6,600,000		6,600,000
Lilly License Agreement \| AVTX-009 Lilly License Agreement
Other Commitments [Line Items]
Milestone payments	$ 70,000,000.0									10,000,000.0			10,000,000.0
Maximum aggregate milestone payment	$ 650,000,000.0
License agreement term	120 days
Research and development expense													10,000,000.0
Cumulative expense recognized to date										10,000,000.0			10,000,000.0
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Minimum
Other Commitments [Line Items]
License agreement royalties (as a percent)	5.00%
Lilly License Agreement \| AVTX-009 Lilly License Agreement \| Maximum
Other Commitments [Line Items]
License agreement royalties (as a percent)	15.00%
Kyowa Kirin Co., Ltd. (KKC) \| Minimum \| Contract Termination
Other Commitments [Line Items]
License agreement term				6 months
Kyowa Kirin Co., Ltd. (KKC) \| Maximum \| Contract Termination
Other Commitments [Line Items]
License agreement term				12 months
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Research and development expense										0			0
Cumulative expense recognized to date										0			0
Upfront license fee				$ 10,000,000.0
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone One
Other Commitments [Line Items]
Maximum aggregate milestone payment				112,500,000
Kyowa Kirin Co., Ltd. (KKC) \| AVTX-002 KKC License Agreement \| Milestone Two
Other Commitments [Line Items]
Maximum aggregate milestone payment				$ 75,000,000.0
CHOP License Agreement
Other Commitments [Line Items]
Collaborative arrangement, royalty term					15 years
CHOP License Agreement \| Contract Termination
Other Commitments [Line Items]
License agreement term					6 months
CHOP License Agreement \| AVTX-002 KKC License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment										1,300,000			1,300,000
Upfront license fee					$ 500,000
Payments for legal settlements					1,000,000.0
License fee					$ 200,000
Astellas Pharma, Inc. (Astellas)
Other Commitments [Line Items]
License agreement term						60 days
Astellas Pharma, Inc. (Astellas) \| AVTX-006
Other Commitments [Line Items]
Licensed product expiration term						10 years
Astellas Pharma, Inc. (Astellas) \| AVTX-006 Astellas License Agreement
Other Commitments [Line Items]
Maximum aggregate milestone payment						$ 5,500,000
Research and development expense										0			0
Cumulative expense recognized to date										500,000			500,000
Upfront license fee						$ 500,000
Alto \| AVTX-301 Out-License
Other Commitments [Line Items]
Maximum proceeds from milestones			$ 18,600,000
Revenue recognized from milestones to date										0			0
ES \| AVTX-406 License Assignment
Other Commitments [Line Items]
Revenue recognized from milestones to date										$ 0			$ 0
ES \| Milestone One \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones																	$ 6,000,000.0
ES \| Milestone Two \| AVTX-406 License Assignment
Other Commitments [Line Items]
Maximum proceeds from milestones																	$ 20,000,000.0
AUG Therapeutics, LLC \| Purchase Agreement \| AVTX-800 Series Asset Sale
Other Commitments [Line Items]
Upfront payment paid		$ 200,000
Asset acquisition consideration transferred, liabilities		$ 400,000
Contingent milestone upfront payment (as a percent)		0.20
Contingent milestone payment		$ 15,000,000.0
Maximum potential payments		$ 45,000,000.0